Ask Warren

GC Biopharma

006280 · KOSPI · ₩006280 · 녹십자

₩130,500▲ ₩1,400 (1.08%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −2.10%
TP5 ₩169,000TP4 ₩155,400TP3 ₩148,600TP2 ₩141,800✅ TP1 ₩137,200Entry ₩132,700DCA1 ₩130,400DCA2 ₩128,200DCA3 ₩125,900STOP ₩123,600
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
Market cap
₩1.5T
Enterprise value
₩2.3T
P/E
—
P/B
1.2×
Dividend yield
0.0%
ROE
−4.0%
Net margin
−2.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−29.0% from the high

₩105,900Today: ₩129,000 – ₩132,700₩183,800

Returns

  • 1W−0.7%
  • 1M+5.9%
  • 3M+15.3%
  • 6M−6.3%
  • YTD−17.9%
  • 1Y−2.1%
Volume today
13,025
0.6× the 20-day average
Traded today
₩1.7B
Listed shares
11,686,538
EPS (12 months)
−₩4,270
Earnings yield −3.3%
SellBuy
AI research · InitiationGC Biopharma: Revenue near ₩2.0T, thin operating margin and net losses, shares at 1.2x bookThe evidence is mixed.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

36Quiet
  • BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
  • MomentumStrong5.8% over the last month; the price is above its 20-day average.
  • News impactSome6 news items and filings in two weeks; 0 rated high impact, 3 medium.
  • StreetSteady3 brokers, average target 40% from the price; last 30 days: 0 raised, 0 cut.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩273M at the close (10.1% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 8 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 4.3% of trading value and pointed the same way 4 of 8 times.

  • 2× KODEX Leverage ₩149M
  • -2× KODEX 200 Futures Inverse 2X ₩71M
  • -1× KODEX Inverse ₩25M
  • 2× TIGER Leverage ₩9.1M
  • 2× TIGER 200IT Leverage ₩8.9M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 32 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 131,500

Basis +0.77% · implied rate +18.6%

Open interest 2,197 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

GC Biopharma stock overview

GC Biopharma (녹십자, KRX: 006280) is listed on KOSPI, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals, centered on blood products and vaccines, along with prescription drugs and over-the-counter medicines. Its shares closed at ₩130,500 on Oct 28, 2026, up 1.08% on the day, giving it a market value of ₩1.5T.

Key facts

Market cap
₩1.5T
Sector
Biotech & Pharma
Latest price change
+1.08%
As of
Oct 28, 2026
Main business
The company manufactures and sells pharmaceuticals, centered on blood products and vaccines, along with prescription drugs and over-the-counter medicines.

Quick answers about GC Biopharma

What does GC Biopharma do?
The company manufactures and sells pharmaceuticals, centered on blood products and vaccines, along with prescription drugs and over-the-counter medicines. Its main customers include general hospitals, clinics, reagent wholesalers, pharmacies, and the Korean Red Cross. It also offers blood and genetic diagnostic and analysis services, and it sells blood products such as ALYGLO in the United States and other markets.
What is the market cap of GC Biopharma?
The market capitalisation of GC Biopharma was ₩1.5T at the close on Oct 28, 2026.
What is the analyst target price for GC Biopharma?
The average target price of 3 brokers covering GC Biopharma is ₩183,333 (range ₩180,000 to ₩190,000), 40.5% above versus the latest price, based on each broker's latest public report within six months.
Who are the largest shareholders of GC Biopharma?
According to the latest official filings, the largest reported holders are National Pension Service (6.68%, as of Jul 1, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.68%, as of Jul 31, 2026); iShares Core MSCI Emerging Markets ETF (0.61%, as of May 31, 2026).
When is the next earnings report from GC Biopharma?
Korean companies rarely announce results dates in advance. Based on when GC Biopharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own GC Biopharma?
Yes. The National Pension Service held 6.68% of GC Biopharma shares as of Jul 1, 2026.

Company profile

The company manufactures and sells pharmaceuticals, centered on blood products and vaccines, along with prescription drugs and over-the-counter medicines. Its main customers include general hospitals, clinics, reagent wholesalers, pharmacies, and the Korean Red Cross. It also offers blood and genetic diagnostic and analysis services, and it sells blood products such as ALYGLO in the United States and other markets.

Written by AI from the company's latest annual report.

Korean name
녹십자
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Contract drug manufacturing (CDMO)
CEO
허은철
Founded
Nov 1969
Listed
Aug 1989
Listed shares
11,686,538
Fiscal year ends
Month 12
Website
www.gcbiopharma.com

Similar companies

Recent news

News · Etoday·

Will GC Biopharma's Administrative Lawsuit Loss Be Overturned? Constitutional Court Holds First Hearing on Constitutional Complaint Against Court Ruling

GC Biopharma₩130,500▲1.08%
Read the original ↗

Predicted impact: Medium

Constitutional Court first hearing on the same vaccine collusion case; the case is already known, so the level is lowered.

News · Money Today·

GC Biopharma Lost Administrative Suit Despite Acquittal in Criminal Collusion Trial: Key Issues in Constitutional Complaint

GC Biopharma₩130,500▲1.08%
Read the original ↗

Predicted impact: Medium

Administrative suit lost despite criminal acquittal; constitutional complaint pending, with prior coverage lowering the level.

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: GC Biopharma / 녹십자 / 006280 / KRX:006280

Source: KRX statistical information